/

Other

/

Acino

Acino

Acino

Verified Nov 2026

Other

·

Switzerland flag

Zurich, Zurich

·

Since 1836

Acino is a Swiss pharmaceutical company headquartered in Zurich, founded in 1836, with 1,000–5,000 employees and estimated revenue of $500M–$1B. It develops and manufactures pharmaceuticals and biosimilar products for emerging markets across Africa, the Middle East, and Latin America. The company operates as a contract development and manufacturing organization, offering drug delivery technologies including modified-release formulations and transdermal patches. In July 2026, Acino partnered with Novo Nordisk to launch South Africa's first authorized semaglutide biosimilar.

Acino

Verified Nov 2026

AT A GLANCE

Founded

1836

Headquarters

Switzerland flag

Zurich, Zurich

Employees

1,000-5,000

Ownership

Acino at a glance

Revenue

$500M-1B

Est. band

Employees

1,000-5,000

Founded

1836

Headquarters

Zurich, Zurich

Industries

Automotive

Electric Vehicles

Medical

Industrial Equipment

Overview

Acino is a Swiss pharmaceutical company headquartered in Zurich, founded in 1836, with 1,000–5,000 employees and estimated revenue of $500M–$1B. It develops and manufactures pharmaceuticals and biosimilar products for emerging markets across Africa, the Middle East, and Latin America. The company operates as a contract development and manufacturing organization, offering drug delivery technologies including modified-release formulations and transdermal patches. In July 2026, Acino partnered with Novo Nordisk to launch South Africa's first authorized semaglutide biosimilar.

At a glance

Attribute

Detail

Founded

1836

Headquarters

Zurich, Zurich

Employees

1,000-5,000

Revenue

$500M-1B (estimated)

What Acino makes

Acino manufactures novel drug delivery forms including modified-release oral formulations, transdermal patches, and biodegradable implants across therapeutic areas such as oncology, cardiology, and gastroenterology.

Products and capabilities described on the company's own site include Assembly, Plastic, Aluminum, Glass (source: acino.swiss).

Latest developments

Company details

The company operates manufacturing facilities in Switzerland, Ukraine, Estonia, South Africa, and Dubai, serving healthcare systems and partnering with major pharmaceutical companies for contract manufacturing and product development. Acino was founded in 1836, has an estimated 1,000-5,000 employees, and is headquartered in Zurich, Zurich.

Frequently asked questions

What does Acino do?

Acino is a Swiss pharmaceutical company headquartered in Zurich, founded in 1836, with 1,000–5,000 employees and estimated revenue of $500M–$1B. It develops and manufactures pharmaceuticals and biosimilar products for emerging markets across Africa, the Middle East, and Latin America. The company operates as a contract development and manufacturing organization, offering drug delivery technologies including modified-release formulations and transdermal patches. In July 2026, Acino partnered with Novo Nordisk to launch South Africa's first authorized semaglutide biosimilar.

Where is Acino headquartered?

Acino is headquartered in Zurich, Zurich (36 Thurgauerstrasse, Zurich, Zurich, 8050).

When was Acino founded?

Acino was founded in 1836.

How big is Acino?

Acino has an estimated 1,000-5,000 employees, with revenue in the $500M-1B range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Zurich, Zurich (HQ)Headquarters · Switzerland
Zurich, Zurich (HQ)36 Thurgauerstrasse, Zurich, Zurich, 8050, SwitzerlandHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.